Literature DB >> 24101017

Management of early-stage esophageal neoplasia (MESEN) consensus.

Alejandro Nieponice1, Adolfo E Badaloni, Blair A Jobe, Toshitaka Hoppo, Carlos Pellegrini, Vic Velanovich, Gary W Falk, Kevin Reavis, Lee Swanstrom, Virender K Sharma, Fabio Nachman, Franco F Ciotola, Luis E Caro, Cecilio Cerisoli, Demetrio Cavadas, Luis Durand Figueroa, Daniel Pirchi, Michael Gibson, Santiago Elizalde, Henry Cohen.   

Abstract

BACKGROUND: Treatment of esophageal adenocarcinoma often involves surgical resection. Newer technologies in interventional endoscopy have led to a substantial paradigm shift in the management of early-stage neoplasia in Barrett's esophagus comprising high-grade dysplasia (HGD), intramucosal carcinoma, and, in some cases, submucosal carcinoma. However, there has been no consensus regarding the indications for esophageal preservation in these cases. In this work, consensus guidelines were established for the management of early-stage esophageal neoplasia considering clinically relevant aspects (age, comorbidities, and social environment) in each scenario.
METHODS: Seventeen experts were invited to participate based on their background and clinical expertise at high-volume centers. A questionnaire was created that included four clinical scenarios covering a wide range of situations within HGD and/or early esophageal neoplasia, particularly where controversies are likely to exist. Each of the clinical scenarios was open to discussion subdivided by patient age (20, 50, and 80 s). For each clinical scenario an expert was chosen to defend that position. Each defense triggered a subsequent discussion during a consensus meeting. Conclusions of that discussion together with an accompanying literature analysis allowed experts to confirm or change their original choices and served as the basis for the recommendations stated in this article.
RESULTS: There was 100 % consensus supporting esophageal preservation in patients with HGD, independent of patient age or Barrett's length. In patients with T1a adenocarcinoma, consensus for preservation was not reached (65 %) for young and middle-aged individuals but was supported for elderly patients (100 %). For T1b adenocarcinoma, consensus was reached for surgical resection (90 %), leaving organ preservation for patients with very low risk of nodal invasion or poor surgical candidates.
CONCLUSION: Advances in endoscopic imaging and therapy allow for organ preservation in most settings of early-stage neoplasia of the esophagus, provided that the patient understands the implications of this decision.

Entities:  

Mesh:

Year:  2014        PMID: 24101017     DOI: 10.1007/s00268-013-2235-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  54 in total

1.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 2.  A systematic review of the evidence for radiofrequency ablation for Barrett's esophagus.

Authors:  Thomas Semlitsch; Klaus Jeitler; Rainer Schoefl; Karl Horvath; Nicole Pignitter; Franz Harnoncourt; Andrea Siebenhofer
Journal:  Surg Endosc       Date:  2010-05-13       Impact factor: 4.584

3.  Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus.

Authors:  P K Nijhawan; K K Wang
Journal:  Gastrointest Endosc       Date:  2000-09       Impact factor: 9.427

4.  Trimodal imaging-assisted endoscopic mucosal resection of early Barrett's neoplasia.

Authors:  T Thomas; R Singh; K Ragunath
Journal:  Surg Endosc       Date:  2009-03-19       Impact factor: 4.584

5.  Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation.

Authors:  Eric S Orman; Hannah P Kim; William J Bulsiewicz; Cary C Cotton; Evan S Dellon; Melissa B Spacek; Xiaoxin Chen; Ryan D Madanick; Sarina Pasricha; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2012-12-18       Impact factor: 10.864

6.  Management of Barrett's esophagus.

Authors:  A A Rahman; R Singh; P Sharma
Journal:  Minerva Gastroenterol Dietol       Date:  2013-03

7.  Detection of intestinal metaplasia in distal esophagus and esophagogastric junction by enhanced-magnification endoscopy.

Authors:  Hideki Toyoda; Carlos Rubio; Ragnar Befrits; Norihiro Hamamoto; Yukihiko Adachi; Edgar Jaramillo
Journal:  Gastrointest Endosc       Date:  2004-01       Impact factor: 9.427

Review 8.  Barrett's esophagus and Barrett's-related dysplasia.

Authors:  John R Goldblum
Journal:  Mod Pathol       Date:  2003-04       Impact factor: 7.842

9.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

10.  Minimally invasive esophagectomy: outcomes in 222 patients.

Authors:  James D Luketich; Miguel Alvelo-Rivera; Percival O Buenaventura; Neil A Christie; James S McCaughan; Virginia R Litle; Philip R Schauer; John M Close; Hiran C Fernando
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

View more
  1 in total

Review 1.  The impact of flexible endoscopy in esophageal surgery.

Authors:  Alejandro Nieponice; Fabio Nachman; Adolfo Badaloni; Franco Ciotola; Cecilia Zubieta; Mauricio Ramirez
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.